Oruka raises $180M; ORKA-001 Phase 1 shows ~100-day half-life, supports annual dosing

Oruka Therapeutics, Inc.

Private placement gross proceeds ~$180M; issued 10.9M shares at $15.00 and pre-funded warrants for 1.07M shares.
ORKA-001 half-life ~100 days (>3x risankizumab), PK supports potential once-yearly maintenance dosing.
Phase 1 showed complete STAT3 inhibition through 24 weeks; no severe TEAEs; safety consistent with IL-23 class.
EVERLAST-A Phase 2a enrollment ongoing, data expected 2H 2026; EVERLAST-B Phase 2b to start 1H 2026.
Pro forma shares outstanding ~67.1M; cash expected to fund into 2027 after key data readouts.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Oruka Therapeutics, Inc. issued 10,933,405 shares of common stock to certain institutional and accredited investors for price per share of $15.00.

Security: common stock
Shares: 10,933,405 shares
Purchaser: certain institutional and accredited investors
Consideration: price per share of $15.00

Exact text from the filing

an aggregate of 10,933,405 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price per share of $15.00

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Oruka Therapeutics, Inc. issued 1,066,666 shares of Common Stock of warrant to certain institutional and accredited investors for purchase price of $14.999 per Pre-Funded Warrant.

Security: warrant
Shares: 1,066,666 shares of Common Stock
Purchaser: certain institutional and accredited investors
Consideration: purchase price of $14.999 per Pre-Funded Warrant

Exact text from the filing

pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 1,066,666 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $14.999 per Pre-Funded Warrant

View on SEC.gov

Browse all equity issuances →

Oruka Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-090129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.